Amazing work from the BITOX to treat patients with immunotherapy – Belgian Society of Medical Oncology
Belgian Society of Medical Oncology shared a post by BITOX, adding:
“Amazing work from the BITOX by Belgian Society of Medical Oncology to treat patients with immunotherapy. We enjoyed the 100th meeting on Monday and beautiful publication on Tuesday. What an exciting week.”
Quoting BITOX‘s post:
“Just published: a retrospective, descriptive analysis of the 246 BITOX cases discussed over the last 3 years, including details on how Sandrine Aspeslagh created this unique national multidisciplinary board in 2021.
A virtual board is feasible and enhances irAE management
Neurological and rheumatological irAEs are most frequently discussed
Dysimmunity is present in many real-world patients
None of this would have been possible without our excellent team and the continuous trust of the Belgian oncologists. Read it here.”
“Three-year analysis of the Belgian multidisciplinary immunotoxicity (BITOX) board: organization, feasibility, and results”
Authors: M. Verhaert, Y. Aydogan, S. Aspeslagh
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023